Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2024-10-23 DOI:10.1111/iju.15612

So Inamura, Yusuke Fukiage, Hisato Kobayashi, Manami Tsutsumiuchi, Masaya Seki, Minekatsu Taga, Masato Fukushima, Motohiro Kobayashi, Osamu Yokoyama, Naoki Terada

{"title":"Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia","authors":"So Inamura, Yusuke Fukiage, Hisato Kobayashi, Manami Tsutsumiuchi, Masaya Seki, Minekatsu Taga, Masato Fukushima, Motohiro Kobayashi, Osamu Yokoyama, Naoki Terada","doi":"10.1111/iju.15612","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; <i>p</i> < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.</p>\n </section>\n </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"151-157"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.15612","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/iju.15612","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.

Materials and Methods

Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.

Results

Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; p < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.

Conclusions

The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.

Abstract Image

查看原文本刊更多论文

5α还原酶抑制剂度他雄胺可能与良性前列腺增生患者的炎症加剧有关。

背景：α-1受体阻滞剂和度他雄胺被广泛用于治疗良性前列腺增生症（BPH），但这些药物对前列腺炎症的影响尚不清楚。在此，我们研究了α-1受体阻滞剂和度他雄胺治疗良性前列腺增生症对前列腺炎症程度的影响：组织标本取自 143 名前列腺增生症患者，这些患者在手术前一直服用α-1 受体阻滞剂。其中 33 名患者在手术前还接受过度他雄胺治疗。前列腺炎症的程度通过高内皮静脉（HEV）样血管的比例进行组织学量化。我们将这一回顾性队列分为α-1受体阻滞剂单药治疗组和联合治疗组（α-1受体阻滞剂+度他雄胺），并评估了两组临床参数与慢性前列腺炎症程度的关系。同时，我们还评估了加重慢性前列腺炎症的因素：结果：单一疗法组和联合疗法组的尿动力学研究参数和慢性前列腺炎症程度比较无显著差异，而联合疗法组的IPSS总分、排尿亚分、夜尿、间歇性排尿、尿流无力和排尿费力均显著低于单一疗法组。α-1受体阻滞剂的用药时间与HEV样血管的比例无关，而度他雄胺的用药时间与HEV样血管的比例密切相关（相关系数=0.595；P 结论：α-1受体阻滞剂与HEV样血管的比例无关，而度他雄胺与HEV样血管的比例密切相关：本研究表明，尽管度他雄胺对前列腺增生有改善作用，但它对慢性前列腺炎症有明显的促进作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.